News

Absolute Risk of Atypical Fractures is Low in Bisphosphonate Users

Publish date: March 8, 2011

 

FROM JAMA

One of the coauthors – Muhammad M. Mamdani, Pharm.D., – reported financial relationships with Boehringer Ingelheim, Janssen-Ortho, Novartis, and Pfizer. The study was funded by the Ontario Ministry of Health and Long-Term Care.

Pages

Recommended Reading

Overweight Patients Need to Hear It From Their Physicians
MDedge Internal Medicine
Nurse-Practitioner vs. Physician Weight Counseling: No Difference
MDedge Internal Medicine
Genetic Variants Linked to Type 2 Diabetes
MDedge Internal Medicine
Intensive Glucose Lowering Linked With Mortality in High Risk Type 2 Diabetes Patients
MDedge Internal Medicine
Diabetes Linked With Risk of Premature Death
MDedge Internal Medicine
Raised Cortisol Levels Later in the Day May Predict Cardiovascular Deaths
MDedge Internal Medicine
Acute Hepatitis B Incidence Double in People With Diabetes
MDedge Internal Medicine
Nondiabetic Gastric Bypass Patients May Develop Hypoglycemia
MDedge Internal Medicine
YMCAs Branch Out to Offer Diabetes Prevention Programs
MDedge Internal Medicine
Zoledronic Acid Cuts Fractures in Osteoporotic Women at All Fracture-Risk Levels
MDedge Internal Medicine